Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun;13(2):364-376.
doi: 10.1007/s13679-024-00551-6.

Update on Endoscopic Treatments for Obesity

Fernanda Pessorrusso  1 , Sagar V Mehta  2 , Shelby Sullivan  3
Affiliations
Review

Update on Endoscopic Treatments for Obesity

Fernanda Pessorrusso et al. Curr Obes Rep. 2024 Jun.

Abstract

Purpose of review: Increased morbidity seen with rising obesity rates continues to place an unheralded burden on our health system. Lack of higher bariatric surgery utilization and limitations with lifestyle modification and pharmacotherapy highlights the need for additional therapies for obesity. Endoscopic bariatric and metabolic therapies (EBMT) are effective, safe treatments for obesity. Current FDA-approved EBMT are confined to gastric modalities while small bowel directed therapies are still considered investigational. This review highlights current modalities of EBMT.

Recent findings: Many randomized controlled trials have been performed, including both open label and sham-controlled, which have demonstrated safety and efficacy of EBMT over lifestyle therapy alone. In addition, emerging evidence from clinical experience further supports EBMT for treatment of obesity. Current evidence supports the safety and efficacy of EBMT for obesity treatment in conjunction with lifestyle therapy. They can also be used concurrently with weight loss medications to increase total weight loss.

Keywords: Aspiration therapy; Bariatric endoscopy; Endoscopic sleeve gastroplasty; Intragastric balloon; POSE.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief. 2020;360:1–8. Epub 2020/06/04 PubMed PMID: 32487284.
    1. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity (Silver Spring). 2014;22(1):5-13. https://doi.org/10.1002/oby.20662 . Epub 2013/12/07. PubMed PMID: 24307184; PMCID: PMC3904491.
    1. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677–86. https://doi.org/10.1016/s0140-6736(09)61457-4 . PubMed PMID: 19878986; PMCID: PMC3135022. - DOI - PubMed
    1. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. Jama. 2016;315(22):2424–34. https://doi.org/10.1001/jama.2016.7602 . Epub 2016/06/15. PubMed PMID: 27299618; PMCID: PMC5617638. - DOI - PubMed - PMC
    1. Dong Z, Xu L, Liu H, Lv Y, Zheng Q, Li L. Comparative efficacy of five long-term weight loss drugs: quantitative information for medication guidelines. Obes Rev. 2017;18(12):1377–85. https://doi.org/10.1111/obr.12606 . Epub 2017/10/13 PubMed PMID: 29024559. - DOI - PubMed

Substances